Molecular targets for the treatment of wounds, in particular chronic wounds

US10071097B2 · kind B2 · utility

Assignees

• URGO RECHERCHE INNOVATION ET DEVELOPPEMENT · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• ECOLE NORMALE SUPERIEURE · FR

Inventors

• Claire Dugast-Darzacq · Antony, FR
• Maïté Noizet · Versailles, FR
• Xavier Darzacq · Antony, FR
• Beatrice Spiluttini Hebert · Houilles, FR

Key dates

• Filing date: Jul 30, 2014
• Grant date: Sep 11, 2018
• Expiry date: Jul 30, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologs thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologs thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.